Advertisement

Topics

Public offerings net $383.4mm for Intercept Pharmaceuticals

15:40 EDT 13 May 2019 | Elsevier Business Intelligence

Intercept Pharmaceuticals Inc. (developing treatments for primary biliary cholangitis, NASH, and primary sclerosing cholangit...

Original Article: Public offerings net $383.4mm for Intercept Pharmaceuticals

NEXT ARTICLE

More From BioPortfolio on "Public offerings net $383.4mm for Intercept Pharmaceuticals"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...